Matching articles for "piperacillin/tazobactam"
Issue 1758 · July 6, 2026
Fosfomycin (Contepo) for Complicated Urinary Tract Infections

The FDA has approved an IV formulation of the epoxide antibacterial drug fosfomycin ( Contepo – Meitheal) for treatment of adults with complicated urinary tract infections (cUTIs) caused by susceptible…

Med Lett Drugs Ther. 2026 Jul 6; 68(1758):107-8 doi:10.58347/tml.2026.1758b
The FDA has approved an IV formulation of the epoxide antibacterial drug fosfomycin ( Contepo – Meitheal) for treatment of adults with complicated urinary tract infections (cUTIs) caused by susceptible isolates of Escherichia coli or Klebsiella pneumoniae . Oral fosfomycin has been available in the US for years for treatment of uncomplicated urinary tract infections. IV fosfomycin has been available in other countries for decades.
Issue 1748 · February 16, 2026
Aztreonam/Avibactam (Emblaveo) for Complicated Intra-Abdominal Infections

The FDA has approved Emblaveo (Abbvie) , an intravenously administered fixed-dose combination of the monobactam antibacterial drug aztreonam and the beta-lactamase inhibitor avibactam, for use with…

Med Lett Drugs Ther. 2026 Feb 16; 68(1748):25-7 doi:10.58347/tml.2026.1748a
The FDA has approved Emblaveo (Abbvie) , an intravenously administered fixed-dose combination of the monobactam antibacterial drug aztreonam and the beta-lactamase inhibitor avibactam, for use with metronidazole to treat complicated intra-abdominal infections (cIAIs) in adults.
Issue 1707 · July 22, 2024
Cefepime/Enmetazobactam (Exblifep) for Complicated Urinary Tract Infections

The FDA has approved Exblifep (Allecra), a fixed-dose combination of the cephalosporin cefepime and the beta-lactamase inhibitor enmetazobactam, for IV treatment of adults with complicated urinary tract…

Med Lett Drugs Ther. 2024 Jul 22; 66(1707):117-8 doi:10.58347/tml.2024.1707d
The FDA has approved Exblifep (Allecra), a fixed-dose combination of the cephalosporin cefepime and the beta-lactamase inhibitor enmetazobactam, for IV treatment of adults with complicated urinary tract infections (cUTIs), including pyelonephritis, caused by designated susceptible microorganisms (see Spectrum of Activity). Exblifep is the first product that contains enmetazobactam to be approved in the US.
Issue 1616 · January 25, 2021 Free
Antibacterial Drugs for Community-Acquired Pneumonia

Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in…

Med Lett Drugs Ther. 2021 Jan 25; 63(1616):10-5
Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in Table 2; recommended antibiotic dosages for treatment of CAP are listed in Tables 3 and 4. Joint guidelines for treatment of CAP by the American Thoracic Society and the Infectious Diseases Society of America (ATS/IDSA) were updated in 2019.
Issue 1597 · May 4, 2020
Cefiderocol (Fetroja) - A New IV Cephalosporin for Complicated UTI

The FDA has approved cefiderocol ( Fetroja – Shionogi), a new IV cephalosporin antibiotic, for treatment of complicated urinary tract infections (UTI) caused by susceptible gram-negative bacteria in adults…

Med Lett Drugs Ther. 2020 May 4; 62(1597):65-8
The FDA has approved cefiderocol ( Fetroja – Shionogi), a new IV cephalosporin antibiotic, for treatment of complicated urinary tract infections (UTI) caused by susceptible gram-negative bacteria in adults who have limited or no alternative treatment options.
Issue 1570 · April 22, 2019
Eravacycline (Xerava) - An IV Tetracycline for Complicated Intra-Abdominal Infections

Eravacycline ( Xerava – Tetraphase), a new synthetic tetracycline antibiotic, has been approved by the FDA for IV treatment of complicated intra-abdominal infections (cIAIs) in adults. Eravacycline is…

Med Lett Drugs Ther. 2019 Apr 22; 61(1570):61-3
Eravacycline ( Xerava – Tetraphase), a new synthetic tetracycline antibiotic, has been approved by the FDA for IV treatment of complicated intra-abdominal infections (cIAIs) in adults. Eravacycline is structurally similar to tigecycline ( Tygacil , and generics), a broad-spectrum tetracycline approved by the FDA for IV treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired pneumonia. A higher rate of mortality has been reported with use of tigecycline compared to other antibacterial drugs; it should be used only when no suitable alternative is available.
Issue 1559 · November 5, 2018
Plazomicin (Zemdri) - A New Aminoglycoside Antibiotic

The FDA has approved the new aminoglycoside antibiotic plazomicin ( Zemdri – Achaogen) for IV treatment of adults with complicated urinary tract infections (cUTIs). Plazomicin is active against multi-drug-…

Med Lett Drugs Ther. 2018 Nov 5; 60(1559):180-2
The FDA has approved the new aminoglycoside antibiotic plazomicin ( Zemdri – Achaogen) for IV treatment of adults with complicated urinary tract infections (cUTIs). Plazomicin is active against multi-drug- resistant Enterobacteriaceae, including strains resistant to other aminoglycosides.
Issue 1549 · June 18, 2018
Meropenem/Vaborbactam (Vabomere) for Complicated Urinary Tract Infection

The FDA has approved a fixed-dose combination of meropenem, a carbapenem antibiotic, and vaborbactam, a new beta-lactamase inhibitor ( Vabomere – Melinta), for IV treatment of adults with complicated urinary…

Med Lett Drugs Ther. 2018 Jun 18; 60(1549):103-5
The FDA has approved a fixed-dose combination of meropenem, a carbapenem antibiotic, and vaborbactam, a new beta-lactamase inhibitor ( Vabomere – Melinta), for IV treatment of adults with complicated urinary tract infections (UTIs) that are proven or strongly suspected to be caused by Escherichia coli , Klebsiella pneumoniae , or Enterobacter cloacae spp. complex. Meropenem ( Merrem , and generics) has been approved for years for treatment of complicated skin and skin structure infections, intra-abdominal infections, and bacterial meningitis. Resistance to meropenem and other carbapenems, mainly due to production of carbapenemases and other extended-spectrum beta-lactamases (ESBLs), has been increasing worldwide, particularly among Enterobacteriaceae. Vabomere is the first carbapenem/beta-lactamase inhibitor combination to be marketed in the US.
Issue 1532 · October 23, 2017
Drugs for Common Bacterial Infections in Adults

Bacterial infections in adults are generally treated empirically, with the antibiotic covering most, but not all, of the potential causative pathogens. For some infections, culture and sensitivity testing can…

Med Lett Drugs Ther. 2017 Oct 23; 59(1532):171-7
Bacterial infections in adults are generally treated empirically, with the antibiotic covering most, but not all, of the potential causative pathogens. For some infections, culture and sensitivity testing can guide treatment, allowing for use of narrower-spectrum antibiotics. The recommended dosages and durations of antibiotic treatment for common respiratory, skin, and urinary tract infections are listed in Tables 1-3. Infectious disease experts now recommend shorter treatment durations for many infections to reduce the development of antimicrobial resistance and minimize adverse effects.
Issue 1496 · June 6, 2016
Alternatives to Fluoroquinolones

The FDA has announced that it is requiring changes in the labeling of systemic fluoroquinolones to warn that the risk of serious adverse effects, including tendinitis, peripheral neuropathy and CNS effects,…

Med Lett Drugs Ther. 2016 Jun 6; 58(1496):75-6
The FDA has announced that it is requiring changes in the labeling of systemic fluoroquinolones to warn that the risk of serious adverse effects, including tendinitis, peripheral neuropathy and CNS effects, generally outweighs their benefit for the treatment of acute sinusitis, acute exacerbations of chronic bronchitis, and uncomplicated urinary tract infections. For these infections, the new labels will recommend reserving fluoroquinolones for patients with no other treatment options.
Issue 1469 · May 25, 2015
Ceftazidime/Avibactam (Avycaz) - A New Intravenous Antibiotic

The FDA has approved ceftazidime/avibactam ( Avycaz – Actavis) for IV treatment of complicated urinary tract and intra-abdominal infections in adults who have limited or no other treatment options.…

Med Lett Drugs Ther. 2015 May 25; 57(1469):79-80
The FDA has approved ceftazidime/avibactam ( Avycaz – Actavis) for IV treatment of complicated urinary tract and intra-abdominal infections in adults who have limited or no other treatment options. Ceftolozane/tazobactam ( Zerbaxa – Cubist), another cephalosporin/beta-lactamase inhibitor combination, was approved in 2014.
Issue 1463 · March 2, 2015
Ceftolozane/Tazobactam (Zerbaxa) - A New Intravenous Antibiotic

The FDA has approved ceftolozane/tazobactam ( Zerbaxa – Cubist), a combination of a new cephalosporin antibiotic and a beta-lactamase inhibitor, for intravenous treatment of complicated urinary tract and…

Med Lett Drugs Ther. 2015 Mar 2; 57(1463):31-3
The FDA has approved ceftolozane/tazobactam ( Zerbaxa – Cubist), a combination of a new cephalosporin antibiotic and a beta-lactamase inhibitor, for intravenous treatment of complicated urinary tract and intra-abdominal infections in adults.
Issue 131 · July 1, 2013
Drugs for Bacterial Infections

The text that follows reviews some common bacterial infections and their empiric treatment pending the results of culture and susceptibility testing. The recommendations made here are based on the results of…

Treat Guidel Med Lett. 2013 Jul; 11(131):65-74
The text that follows reviews some common bacterial infections and their empiric treatment pending the results of culture and susceptibility testing. The recommendations made here are based on the results of susceptibility studies, clinical trials, and the opinions of Medical Letter reviewers. Tables 1 and 2 list the usual dosages of antibacterial drugs.
Issue 1395 · July 23, 2012
Drugs for Urinary Tract Infections

The most recent guidelines from the Infectious Diseases Society of America (IDSA) and its European counterpart on the choice of antimicrobials for treatment of uncomplicated urinary tract infections (UTIs) in…

Med Lett Drugs Ther. 2012 Jul 23; 54(1395):57-8
The most recent guidelines from the Infectious Diseases Society of America (IDSA) and its European counterpart on the choice of antimicrobials for treatment of uncomplicated urinary tract infections (UTIs) in non-pregnant women focus on the unnecessary use of fluoroquinolones to treat uropathogens that are increasingly becoming resistant to them. Resistance of Escherichia coli to ciprofloxacin in the US has increased from 3% in 2000 to 17.1% in 2010.
Issue 1356 · January 24, 2011
Ceftaroline Fosamil (Teflaro) - A New IV Cephalosporin

The FDA has approved ceftaroline fosamil ( Teflaro – Forest), an intravenous (IV) cephalosporin, for treatment of acute bacterial skin and skin structure infections, including those caused by…

Med Lett Drugs Ther. 2011 Jan 24; 53(1356):5-6
The FDA has approved ceftaroline fosamil ( Teflaro – Forest), an intravenous (IV) cephalosporin, for treatment of acute bacterial skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA), and for treatment of community-acquired bacterial pneumonia in adults. It is the first beta-lactam antibiotic approved for treatment of MRSA.
Issue 94 · June 1, 2010
Drugs for Bacterial Infections

The text below reviews some common bacterial infections and their treatment. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter…

Treat Guidel Med Lett. 2010 Jun; 8(94):43-52
The text below reviews some common bacterial infections and their treatment. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants.